Get the Stockscreener App
1.34
1.52%
0.02
Pyxis Oncology Inc stock is traded at $1.34, with a volume of 1.33M.
It is up +1.52% in the last 24 hours and up +18.58% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$1.32
Open:
$1.29
24h Volume:
1.33M
Relative Volume:
2.78
Market Cap:
$83.01M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-0.7283
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
+8.94%
1M Performance:
+18.58%
6M Performance:
+4.69%
1Y Performance:
-63.29%
1-Day Range:
$1.28
$1.43
1-Week Range:
$1.14
$1.43
52-Week Range:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.34 | 76.90M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Pyxis Oncology's Promising MICVO Developments and Merck Collaboration Earns Bullish Rating - AInvest
HC Wainwright Reaffirms 'Buy' Rating for Pyxis Oncology with $5 Target Price. - AInvest
Pyxis Oncology Inc. Breaks Below Key Support LevelJuly 2025 Breakouts & AI Driven Stock Reports - thegnnews.com
HC Wainwright Raises PT for Pyxis Oncology to $5 from $5 on Buy Rating - AInvest
Pyxis Oncology Q2 Earnings Miss Worsens Losses, Sparking Mixed Market Reactions - AInvest
Pyxis Oncology Q2 Earnings Disappoint; Mixed Backtest Signals Market Volatility - AInvest
Will Pyxis Oncology Inc. Recover After Recent DeclineWeekly Investment Summary & Entry Point Strategy Guides - beatles.ru
Is Pyxis Oncology Inc. trending in predictive chart modelsTrade Exit Report & Real-Time Volume Spike Alerts - Newser
Custom strategy builders for tracking Pyxis Oncology Inc.July 2025 Recap & Technical Buy Zone Confirmations - Newser
Is Pyxis Oncology Inc. stock risky to hold nowQuarterly Portfolio Report & Expert Curated Trade Ideas - thegnnews.com
Pyxis Oncology Insiders Recover Some Losses, Which Stand At US$65k - simplywall.st
Earnings visualization tools for Pyxis Oncology Inc.CPI Data & Reliable Breakout Forecasts - Newser
Pyxis Oncology Inc. stock prediction for this weekTrade Volume Summary & Detailed Earnings Play Strategies - Newser
How Pyxis Oncology Inc. stock performs during market volatilityJuly 2025 Sector Moves & Stepwise Entry and Exit Trade Signals - Newser
Short interest data insights for Pyxis Oncology Inc.July 2025 Decliners & Fast Entry Momentum Alerts - Newser
Is now a turning point for Pyxis Oncology Inc.Treasury Yields & Real-Time Stock Entry Alerts - Newser
Pyxis Oncology Reports Q2 2025 EPS of ($0.30), Beating Estimates, with Revenue at $2.8 Million - AInvest
William Blair Analyst Reiterates Hold Rating on Pyxis Oncology - AInvest
Custom Dashboard Highlights Pyxis Oncology Inc. Price MomentumJuly 2025 Summary & Community Supported Trade Ideas - 선데이타임즈
How to integrate Pyxis Oncology Inc. into portfolio analysis toolsTrade Exit Summary & Detailed Earnings Play Alerts - Newser
Heatmap analysis for Pyxis Oncology Inc. and competitorsMarket Activity Summary & Daily Entry Point Trade Alerts - Newser
Buy Rating for Pyxis Oncology: Promising Prospects for Micvo and Strong Financial Position - TipRanks
Drawdown in Pyxis Oncology Inc. May Be Nearing End2025 Institutional Moves & High Return Trade Guides - kangso.co.kr
Pyxis Oncology Reports Q2 2025 Financial Results - TipRanks
Pyxis Oncology Reports Q2 2025 Financial Results, Cash Runway Extended to H2 2026. - AInvest
Pyxis Oncology: Navigating Cost Efficiency and Market Potential in the ADC Revolution - AInvest
Pyxis Oncology reports Q2 EPS (30c), consensus (35c) - TipRanks
Pyxis Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pyxis Oncology: A High-Potential Biotech Play with Near-Term Clinical Catalysts and Strengthening Financial Position - AInvest
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - MarketScreener
What makes Pyxis Oncology Inc. stock price move sharply2025 Momentum Check & Long-Term Safe Investment Ideas - mustnews.co.kr
Can Pyxis Oncology Inc. Bounce Back From Weekly LowWall Street Watch & Short-Term Swing Trade Alerts - newsyoung.net
What does recent volatility data suggest for Pyxis Oncology Inc.Portfolio Performance Report & Consistent Return Investment Signals - Newser
Using data models to predict Pyxis Oncology Inc. stock movementMarket Sentiment Summary & Smart Investment Allocation Tips - Newser
Visual analytics tools that track Pyxis Oncology Inc. performanceQuarterly Profit Review & Consistent Return Strategy Ideas - Newser
Pyxis Oncology Inc. stock momentum explainedMarket Rally & Long-Term Growth Stock Strategies - Newser
Statistical indicators supporting Pyxis Oncology Inc.’s strength2025 Pullback Review & Free Verified High Yield Trade Plans - Newser
Heatmap analysis for Pyxis Oncology Inc. and competitors [July 2025 Drop Watch]Weekly Breakout Stock Alerts - Newser
Can Pyxis Oncology Inc. recover in the next quarterEarnings Growth Report & Pattern Based Trade Signal System - Newser
Earnings visualization tools for Pyxis Oncology Inc. [July 2025 Closing Moves]Short-Term Swing Trade Alerts - Newser
Pyxis Oncology (PYXS) Projected to Post Earnings on Wednesday - Defense World
Real time scanner hits for Pyxis Oncology Inc. explainedPredictable Income Summary for Long-Term Trades - Newser
Should you hold or exit Pyxis Oncology Inc. nowPattern Breakout Tracker with Screener Tools - Newser
Pyxis Oncology Inc. stock chart pattern explainedTrend Confirmation Scanner with Entry Focus - Newser
Pyxis Oncology PYXS 2025Q2 Earnings Preview Downside Concerns Amid Revenue Uncertainty - AInvest
Why Pyxis Oncology Inc. stock attracts strong analyst attentionFree Triple Digit Growth Focused Trade Plan - Newser
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):